ARCHIVES

Longer Chemo Regimen Offers Better DFS For Premenopausal Breast Cancer

This article is from The Cancer Letter archive.

Vol. 26 No. 1 | January 31, 2003

Download PDF Visit The Full Archive

Related Articles

Letter to the Editors: BSA P01 Review Vote Was Advisory, NCI Official Says

December 5, 1997

Zelboraf Increased Overall Survival To 15.9 Months in Phase II Study

March 30, 2012

Cancer death rate dropping 1.1 percent a year, annual report finds.

October 7, 2005

Perjeta, Herceptin & Docetaxel Combination Extended Survival in HER2-Positive Disease

December 28, 2012

Next issue of The Cancer Letter is scheduled for Jan. 7, 2005.

December 10, 2004

Sponsors Withdraw Indications for Iressa, Celebrex

February 11, 2011